Literature DB >> 27834501

Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia.

Ping Tang1, Jing Xu2, Bao-Jun Xie2, Qi-Mei Wang1.   

Abstract

OBJECTIVE: Preeclampsia (PE) is a disorder of pregnancy marked by hypertension and proteinuria with no known treatment aside from pregnancy termination. The pathogenesis of PE is poorly understood, but is thought to originate in the placenta. We assessed the value of measuring serum and urinary soluble deformylase-like tyrosine kinase receptor 1 (sFlt-1), a known target of placental factors, and placental growth factor (PLGF), a key placental signaling molecule, in the diagnosis of PE.
METHODS: Eighty patients with PE were classified as either exhibiting mild (44 cases) or severe (36 cases) symptoms of PE. Forty normal pregnant women were selected as controls. Serum and urinary PLGF and sFlt-1 levels, along with the ratio of sFlt-1 to PLGF, were compared across groups.
RESULTS: Serum and urinary sFlt-1 and sFlt-1/PLGF ratios in severe PE patients were significantly higher than those in the mild PE group, and measurements from mild PE patients were significantly higher than controls (all P values <0.01). The serum and urinary PLGF levels in severe PE patients were significantly lower than mild PE patients, and mild PE patients had significantly lower PLGF levels than controls (all P values <0.01). As expected, serum sFlt-1 and PLGF levels and ratios were highly correlated with urinary sFlt-1 and PLGF levels and ratios.
CONCLUSIONS: The severity of PE was closely correlated with these measurements, suggesting that they may be useful tools in the diagnosis and evaluation of PE.

Entities:  

Keywords:  Diagnosis; placenta growth factor; preeclampsia; soluble FMS-like tyrosine kinase receptor 1

Mesh:

Substances:

Year:  2016        PMID: 27834501     DOI: 10.1080/10641955.2016.1237642

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  5 in total

1.  The effects of sildenafil citrate on urinary podocin and nephrin mRNA expression in an L-NAME model of pre-eclampsia.

Authors:  Sooraj Baijnath; Saravanakumar Murugesan; Irene Mackraj; Prem Gathiram; Jagidesa Moodley
Journal:  Mol Cell Biochem       Date:  2016-12-19       Impact factor: 3.396

Review 2.  Preeclampsia and Related Cardiovascular Risk: Common Genetic Background.

Authors:  Michalina Lisowska; Tadeusz Pietrucha; Agata Sakowicz
Journal:  Curr Hypertens Rep       Date:  2018-07-03       Impact factor: 5.369

3.  Abnormal expression and clinical significance of 25-hydroxyvitamin D and sFlt-1 in patients with preeclampsia.

Authors:  Xinhua Chen; Xuxia Xi; Fan Cui; Ming Wen; Aijuan Hong; Zemei Hu; Juan Ni
Journal:  J Int Med Res       Date:  2019-09-12       Impact factor: 1.671

4.  The Diagnostic Efficacy of Thrombelastography (TEG) in Patients with Preeclampsia and its Association with Blood Coagulation.

Authors:  He Lidan; Wu Jianbo; Gao Liqin; Hu Jifen; Lu Lin; Wu Xiuyan
Journal:  Open Life Sci       Date:  2019-07-22       Impact factor: 0.938

5.  A simple detection method for the serum sFLT1 protein in preeclampsia.

Authors:  Masabumi Shibuya; Haruka Matsui; Tadashi Sasagawa; Takeshi Nagamatsu
Journal:  Sci Rep       Date:  2021-10-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.